Monte Rosa Therapeutics doses first patient in Phase 2 prostate study
Monte Rosa Therapeutics announces first patient dosed in MODeFIRe-1, a Phase 2 study of MRT-2359 in combination with apalutamide in AR mutation-positive metastatic castration-resistant prostate cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.